. Author manuscript; available in PMC: 2022 Jun 10.

Published in final edited form as: Clin Cancer Res. 2022 Apr 14;28(8):1586–1594. doi: 10.1158/1078-0432.CCR-21-3874

Table 1.

Patient demographics and tumor characteristics.

	Phase Ib	Phase II
	RO4929097 plus vismodegib	RO4929097	RO4929097 plus vismodegib
Total n	9	34	33
Age (median)	60	56	46
Male sex, n (%)	5 (55.6%)	20 (58.8%)	18 (54.5%)
Histology, n (%)
Liposarcoma	3 (33.3%)	9 (26.5%)	10 (30.3%)
Other^*	8 (66.7%)	25 (73.5%)	23 (69.7%)
ECOG performance status, n (%)
0–1	9 (100%)	34 (100%)	32 (97%)
2	0 (0)	0 (0)	1 (3.0)
Number of prior therapies (median)	4	2	3